Autor: "Alami NN" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Longitudinal Molecular and Serological Evidence of SARS-CoV-2 Infections and Vaccination Status: Community-Based Surveillance Study (CONTACT).
Autorzy:: Sánchez-Soliño O; AbbVie Inc., 26525 Riverwoods Blvd., Mettawa, North Chicago, IL, 60045, USA. .
Kilpatrick RD; AbbVie Inc., North Chicago, IL, USA.
Johnson C; AbbVie Inc., North Chicago, IL, USA.; Amgen, Thousand Oaks, USA.
Fang Y; AbbVie Inc., North Chicago, IL, USA.
Ye Y; AbbVie Inc., North Chicago, IL, USA.
Alami NN; AbbVie Inc., North Chicago, IL, USA.; Pfizer, New York, USA.
Zarish K; AbbVie Inc., North Chicago, IL, USA.
Krueger WS; AbbVie Inc., North Chicago, IL, USA.
Dreyer N; IQVIA Real World Solutions, Cambridge, MA, USA.; Dreyer Strategies, Newton, USA.
Gray GC; Division of Infectious Diseases, School of Medicine, University of Texas Medical Branch, Galveston, TX, USA.; Pokaż więcej
Źródło:: Infectious diseases and therapy [Infect Dis Ther] 2024 Mar 10. Date of Electronic Publication: 2024 Mar 10.
Typ publikacji:: Journal Article

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Phase 1 study of safety, pharmacokinetics, and antiviral activity of SARS-CoV-2 neutralizing monoclonal antibody ABBV-47D11 in patients with COVID-19.
Autorzy:: Shebley M; AbbVie Inc., North Chicago, Illinois, USA.
Wang S; AbbVie Inc., North Chicago, Illinois, USA.
Ali I; AbbVie Inc., North Chicago, Illinois, USA.
Krishnan P; AbbVie Inc., North Chicago, Illinois, USA.
Tripathi R; AbbVie Inc., North Chicago, Illinois, USA.
Reardon JM; Prisma Health Upstate, Greenville, South Carolina, USA.
Cafardi J; The Christ Hospital, Cincinnati, Ohio, USA.
Rahav G; Sheba Medical Center and Tel-Aviv University, Tel Hashomer, Israel.
Caraco Y; Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Slim J; NYMC, Valhalla, New York, USA.
Al Akhrass F; Pikeville Medical Center, Pikeville, Kentucky, USA.
Yu M; AbbVie Inc., North Chicago, Illinois, USA.
Hu Y; AbbVie Inc., North Chicago, Illinois, USA.
Ferreira RA; AbbVie Inc., North Chicago, Illinois, USA.
Alami NN; AbbVie Inc., North Chicago, Illinois, USA.; Pokaż więcej
Źródło:: Pharmacology research & perspectives [Pharmacol Res Perspect] 2023 Feb; Vol. 11 (1), pp. e01036.
Typ publikacji:: Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: COVID-19*
Adult ; Humans ; SARS-CoV-2 ; Antibodies, Monoclonal/pharmacokinetics ; Antiviral Agents ; Antibodies, Neutralizing

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: EpidemiologiCal POpulatioN STudy of SARS-CoV-2 in Lake CounTy, Illinois (CONTACT): Methodology and Baseline Characteristics of a Community-Based Surveillance Study.
Autorzy:: Kilpatrick RD; AbbVie Inc., North Chicago, IL, USA. .; AbbVie, Inc., 26525 Riverwoods Blvd., Mettawa, IL, 60045, USA. .
Sánchez-Soliño O; AbbVie Inc., North Chicago, IL, USA.
Alami NN; AbbVie Inc., North Chicago, IL, USA.
Johnson C; AbbVie Inc., North Chicago, IL, USA.
Fang Y; AbbVie Inc., North Chicago, IL, USA.
Wegrzyn LR; AbbVie Inc., North Chicago, IL, USA.
Krueger WS; AbbVie Inc., North Chicago, IL, USA.
Ye Y; AbbVie Inc., North Chicago, IL, USA.
Dreyer N; IQVIA Real World Solutions, Cambridge, MA, USA.
Gray GC; Division of Infectious Diseases, School of Medicine, Duke University, Durham, NC, USA.; Global Health Institute, Duke University, Durham, NC, USA.; University of Texas Medical Branch, Galveston, TX, USA.; Pokaż więcej
Źródło:: Infectious diseases and therapy [Infect Dis Ther] 2022 Apr; Vol. 11 (2), pp. 899-911. Date of Electronic Publication: 2022 Feb 02.
Typ publikacji:: Journal Article

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study.
Autorzy:: Coutre SE; Stanford Cancer Center, Stanford University School of Medicine, Stanford, California, USA.
Barnett C; MedStar Washington Hospital Center, Washington, District of Columbia, USA.; University of California, San Francisco, San Francisco, California, USA.
Osiyemi O; Triple O Research Institute, West Palm Beach, Florida, USA.
Hoda D; Intermountain Healthcare, Salt Lake City, Utah, USA.
Ramgopal M; Midway Immunology and Research Center, Fort Pierce, Florida, USA.
Fort AC; University of Miami Miller School of Medicine, Miami, Florida, USA.
Qaqish R; AbbVie, North Chicago, Illinois, USA.
Hu Y; AbbVie, North Chicago, Illinois, USA.
Ninomoto J; Pharmacyclics LLC, an AbbVie Company, South San Francisco, California, USA.
Alami NN; AbbVie, North Chicago, Illinois, USA.
Styles L; Pharmacyclics LLC, an AbbVie Company, South San Francisco, California, USA.
Treon SP; Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Pokaż więcej
Źródło:: Open forum infectious diseases [Open Forum Infect Dis] 2022 Mar 24; Vol. 9 (5), pp. ofac104. Date of Electronic Publication: 2022 Mar 24 (Print Publication: 2022).
Typ publikacji:: Journal Article

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials.
Autorzy:: Heo J; Department of Internal Medicine, Pusan National University College of Medicine and Medical Research Institute, Pusan National University Hospital, Busan, Korea.
Kim YJ; Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Lee JW; Department of Internal Medicine, Inha University School of Medicine, Incheon, Korea.
Kim JH; Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Lim YS; Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Han KH; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Jeong SH; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Cho M; Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University College of Medicine, Yangsan, Korea.
Yoon KT; Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University College of Medicine, Yangsan, Korea.
Bae SH; Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Crown ED; Abbvie Inc., North Chicago, IL, USA.
Fredrick LM; Abbvie Inc., North Chicago, IL, USA.
Alami NN; Abbvie Inc., North Chicago, IL, USA.
Asatryan A; Abbvie Inc., North Chicago, IL, USA.
Kim DH; AbbVie Korea, Ltd., Korea.
Paik SW; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Lee YJ; Department of Internal Medicine, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.; Pokaż więcej
Źródło:: Gut and liver [Gut Liver] 2021 Nov 15; Vol. 15 (6), pp. 895-903.
Typ publikacji:: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
MeSH Terms:: Hepatitis C, Chronic*/drug therapy
Aminoisobutyric Acids ; Antiviral Agents/adverse effects ; Benzimidazoles ; Clinical Trials, Phase III as Topic ; Cyclopropanes ; Drug Therapy, Combination ; Genotype ; Hepacivirus/genetics ; Humans ; Lactams, Macrocyclic ; Leucine/analogs & derivatives ; Proline/analogs & derivatives ; Pyrrolidines ; Quinoxalines ; Republic of Korea ; Sulfonamides ; Sustained Virologic Response ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials.
Autorzy:: Grebely J; The Kirby Institute, UNSW Sydney, Sydney, Australia.
Puoti M; Azienda Ospedaliera Ospedale Niguarda Ca' Granda, Milan, Italy.
Wedemeyer H; Medizinische Hochschule Hannover, Hannover, Germany.
Cooper C; Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Sulkowski MS; Viral Hepatitis Center, Johns Hopkins University, Baltimore, Maryland.
Foster GR; Queen Mary University of London and Barts Health NHS Trust, London, United Kingdom.
Berg T; Universitätsklinikum Leipzig, Leipzig, Germany.
Villa E; University of Modena and Reggio Emilia, Modena, Italy.
Rodriguez-Perez F; Gastroenterology Department, VA Caribbean Healthcare System, San Juan, Puerto Rico.
Wyles DL; Infectious Diseases Division, Department of Medicine at Denver Health, Denver, Colorado.
Schnell G; AbbVie Inc., North Chicago, Illinois.
Alami NN; AbbVie Inc., North Chicago, Illinois.
Zhang Z; AbbVie Inc., North Chicago, Illinois.
Dumas E; AbbVie Inc., North Chicago, Illinois.
Dore GJ; The Kirby Institute, UNSW Sydney, Sydney, Australia.; Pokaż więcej
Źródło:: Open forum infectious diseases [Open Forum Infect Dis] 2018 Sep 27; Vol. 5 (11), pp. ofy248. Date of Electronic Publication: 2018 Sep 27 (Print Publication: 2018).
Typ publikacji:: Journal Article